Acute myeloid leukemia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Acute Myeloid Leukemia (AML) is a fast‑growing cancer of the bone marrow and blood that originates from myeloid precursor cells. These immature cells normally develop into red blood cells, white blood cells (neutrophils, eosinophils, basophils, monocytes), and platelets. In AML, the marrow produces large numbers of abnormal, immature myeloid cells (called “myeloblasts”) that do not function properly, crowding out healthy blood cells.

AML can affect anyone, but its incidence rises sharply with age:

• Average age at diagnosis: 68 years.
• Approximately 20,000 new cases are diagnosed annually in the United States (2023 CDC data).
• It accounts for about 1% of all cancers and 15% of adult leukemias worldwide.

While relatively rare compared with solid tumors, AML is a medical emergency because the disease can progress from diagnosis to life‑threatening complications within weeks to months if untreated.

Symptoms

Because AML replaces normal blood cells, its symptoms reflect anemia, thrombocytopenia, and infection. Symptoms can develop quickly and may vary in severity.

General signs

• Fatigue or weakness – due to low red blood cells (anemia).
• Fever or chills – often a sign of infection caused by low neutrophils.
• Unexplained weight loss – despite normal eating habits.
• Night sweats – common in many leukemias.

Bleeding‑related symptoms (low platelets)

• Easy bruising or petechiae (tiny red spots) on the skin.
• Nosebleeds that last longer than usual.
• Bleeding gums or prolonged bleeding from cuts.
• Heavy menstrual bleeding.

Infection‑related symptoms (low neutrophils)

• Frequent or severe infections (e.g., pneumonia, urinary‑tract infections).
• Oral thrush or other fungal infections.

Bone‑marrow and organ involvement

• Bone pain or tenderness, especially in the long bones or ribs.
• Swollen lymph nodes, spleen, or liver (may feel like a fullness in the abdomen).
• Shortness of breath or rapid heartbeat (anemia‑related).

Causes and Risk Factors

Most AML cases are “idiopathic,” meaning no single cause can be identified. However, several genetic, environmental, and medical factors increase risk.

Environmental and occupational exposures

• High‑dose benzene (found in gasoline, rubber manufacturing, and some solvents).
• Exposure to radiation (e.g., atomic bomb survivors, therapeutic radiation).
• Certain chemotherapy agents used for other cancers (alkylating agents, topoisomerase II inhibitors).

Medical conditions

• Pre‑existing myelodysplastic syndromes (MDS) or myeloproliferative neoplasms.
• Previous treatment for other cancers (especially with cyclophosphamide, melphalan, or anthracyclines).
• Inherited bone‑marrow failure syndromes (e.g., Fanconi anemia, Diamond‑Blackfan anemia).

Genetic mutations

Somatic mutations in genes such as FLT3, NPM1, CEBPA, DNMT3A, IDH1/2 are detected in >80% of AML cases and influence prognosis and therapy selection.

Demographic risk factors

• Age – risk rises sharply after 60 years.
• Gender – slightly more common in males (≈1.3:1 male‑to‑female ratio).
• Ethnicity – higher incidence in White and Hispanic populations in the U.S.

Diagnosis

Prompt diagnosis is essential. The work‑up combines clinical evaluation, laboratory testing, and imaging.

Blood tests

• Complete blood count (CBC) with differential – typically shows anemia, low platelets, and abnormal white‑cell counts.
• Peripheral blood smear – reveals circulating blasts (immature cells).
• Lactate dehydrogenase (LDH) – often elevated due to rapid cell turnover.

Bone‑marrow evaluation

• Aspirate and core biopsy – gold‑standard; >20% blasts in marrow confirms AML (WHO criteria).
• Flow cytometry – identifies cell‑surface markers (CD13, CD33, CD117, MPO) that classify AML subtypes.
• Cytogenetic and molecular analysis – detects chromosomal abnormalities (e.g., t(8;21), inv(16), complex karyotype) and gene mutations that guide prognosis and treatment.

Imaging (when indicated)

• Chest X‑ray or CT – assesses infection or leukemic infiltration of lungs.
• Abdominal ultrasound/CT – evaluates spleen or liver enlargement.

Additional assessments

• Baseline cardiac echocardiogram – required before anthracycline chemotherapy.
• Liver and kidney function tests to tailor drug dosing.

Treatment Options

Treatment is individualized based on age, performance status, genetic risk, and comorbidities. The main goals are to achieve complete remission (CR) and, when possible, cure the disease.

Induction chemotherapy

• 7+3 regimen – 7 days of continuous cytarabine (Ara‑C) infusion plus 3 days of an anthracycline (daunorubicin or idarubicin). This classic regimen cures ~50–70% of younger adults.
• Alternative/augmented regimens (e.g., cladribine‑plus‑cytarabine, FLAG‑IDA) for high‑risk or relapsed disease.

Consolidation & post‑remission therapy

• High‑dose cytarabine (HD‑AraC) for favorable‑risk patients.
• All‑ogeneic hematopoietic stem‑cell transplantation (allo‑HSCT) for intermediate‑ or adverse‑risk disease, especially in patients <60–70 years.

Targeted agents (approved 2017‑2024)

• Midostaurin – FLT3 inhibitor, added to induction for FLT3‑mutated AML.
• Gilteritinib – for relapsed/refractory FLT3‑mutated AML.
• Enasidenib – IDH2 inhibitor (mutant IDH2 AML).
• Ivosidenib – IDH1 inhibitor (mutant IDH1 AML).
• Venetoclax – BCL‑2 inhibitor, often combined with hypomethylating agents (azacitidine or decitabine) for older or unfit patients.

Hypomethylating agents (HMAs)

• Azacitidine or decitabine – lower‑intensity options for patients >65 years or those with comorbidities; can be combined with venetoclax (improves CR rates to 60‑70%).

Supportive care

• Transfusion support (RBCs, platelets) to manage anemia and thrombocytopenia.
• Broad‑spectrum antibiotics or antifungals for neutropenic fever.
• Growth‑factor support (e.g., G‑CSF) in selected patients.
• Management of tumor lysis syndrome (IV hydration, allopurinol or rasburicase).

Lifestyle & adjunct measures

• Balanced nutrition, adequate hydration, and gentle exercise as tolerated.
• Smoking cessation – improves response to treatment and reduces infection risk.
• Vaccinations (influenza, pneumococcal) after immune reconstitution.

Living with Acute Myeloid Leukemia

Beyond medical treatment, daily life adjustments help maintain quality of life.

Managing fatigue and energy

• Prioritize rest; break activities into short, frequent sessions.
• Schedule appointments for times of day when you feel most energetic.

Infection prevention

• Practice meticulous hand hygiene and avoid crowded places during neutropenic periods.
• Use a mask in public indoor settings if you are immunocompromised.
• Keep a list of your medications and allergies for emergency staff.

Nutrition

• Eat small, nutrient‑dense meals; focus on protein (lean meats, beans, Greek yogurt).
• Consider a registered dietitian experienced in oncology for individualized plans.
• Stay hydrated – aim for 2–3 L of fluid daily unless fluid‑restricted.

Emotional & psychosocial support

• Join support groups (local hospitals, CancerCare, online forums).
• Consider counseling or cognitive‑behavioral therapy to address anxiety/depression.
• Lean on caregivers; ask for help with household tasks when energy is low.

Follow‑up care

• Regular CBCs every 1–2 weeks during induction, then every 1–3 months after remission.
• Long‑term monitoring for secondary cancers, cardiac function (especially after anthracyclines), and graft‑versus‑host disease if transplanted.

Prevention

Because most AML cases are not preventable, the focus is on reducing modifiable risk factors.

• Avoid high‑level benzene exposure – use protective equipment if you work in gasoline, rubber, or chemical industries.
• Limit unnecessary radiation – discuss alternative imaging with physicians.
• Quit smoking – smoking is linked to an increased leukemia risk.
• Maintain a healthy lifestyle – balanced diet, regular exercise, and weight management support overall immune health.
• For individuals with known genetic predispositions, genetic counseling and regular hematologic surveillance are recommended.

Complications

If AML is left untreated or inadequately controlled, several serious complications can arise.

• Severe infections – neutropenia predisposes to bacterial, fungal, and viral sepsis, a leading cause of early death.
• Bleeding – thrombocytopenia can cause life‑threatening hemorrhage (intracranial, gastrointestinal).
• Anemia‑related heart failure – chronic low oxygen delivery strains the cardiovascular system.
• Leukostasis – very high blast counts (>100 × 10⁹/L) can cause microvascular obstruction, leading to respiratory distress, neurologic deficits, or renal failure.
• Secondary malignancies – especially after chemotherapy or radiation.
• Graft‑versus‑host disease (GVHD) – a risk after allogeneic stem‑cell transplant.

When to Seek Emergency Care

---

Sources: Mayo Clinic, National Cancer Institute, American Cancer Society, CDC Cancer Statistics Brief 2023, WHO Leukemia Fact Sheet 2022, Cleveland Clinic, Blood journal (2021‑2024), New England Journal of Medicine (2022‑2024).

```